Short-term efficacy assessment of transarterial chemoembolization combined with radioactive iodine therapy in primary hepatocellular carcinoma

Table 1 Comparison of changes in tumor lengths in the two groups of patients

Group	n	Before treatment	After 1 mo of treatment	After 3 mo of treatment
Study group	49	6.31 ± 2.00	4.11 ± 1.42	2.20 ± 1.04
Control group	49	6.14 ± 1.89	4.78 ± 1.50	2.81 ± 0.95
t value		0.432	-2.271	-3.031
P value		0.666	0.025	0.003

Data are presented as mean ± SD, in cm. Control group: Treated with transarterial chemoembolization (TACE); Study group: Treated with TACE and radioactive iodine implantation.

Table 2 Comparison of serum alpha-fetoprotein levels in the two groups of patients

Group	n	Before treatment	After 1 mo of treatment	After 3 mo of treatment
Study group	49	549.8 ± 130.7	342.0 ± 96.5	184.3 ± 67.8
Control group	49	530.6 ± 148.0	388.5 ± 86.0	219.5 ± 73.0
t value		0.681	-2.518	-2.473
P value		0.498	0.013	0.015

Data are presented as mean ± SD, in μg/L. Control group: Treated with transarterial chemoembolization (TACE); Study group: Treated with TACE and radioactive iodine implantation.

Table 3 Comparison of treatment efficacy in the two groups

Group	n	CR	PR	SD	PD	CR + PR
Study group	49	15	29	3	0	46 (93.88)
Control group	49	9	29	11	0	38 (77.55)
χ2 value						5.333
P value						0.021

Control group: Treated with transarterial chemoembolization (TACE); Study group: Treated with TACE and radioactive iodine implantation. CR: Complete remission; PD: Progressive disease; PR: Partial remission; SD: Stable disease.

Table 4 Comparison of computed tomography perfusion parameters of the lesions in the two groups of patients

Perfusion parameters	Study group, n = 49	Control group, n = 49	Z value	P value
BV, mL/(100 g/min)
Before treatment	23.16 ± 3.29	22.57 ± 4.02	0.795	0.429
After 3 mo of treatment	8.40 ± 2.20	10.01 ± 2.54	-3.354	0.001
PS, mL/(100 g/min)
Before treatment	27.17 ± 5.48	26.20 ± 5.81	0.850	0.397
After 3 mo of treatment	12.64 ± 2.60	14.20 ± 3.13	-2.684	0.009
BF, mL/(100 g/min)
Before treatment	254.8 ± 58.1	247.6 ± 63.4	0.586	0.559
After 3 mo of treatment	83.0 ± 24.7	100.2 ± 32.5	-2.949	0.004
HAF, %
Before treatment	0.67 ± 0.17	0.64 ± 0.17	0.873	0.385
After 3 mo of treatment	0.24 ± 0.08	0.31 ± 0.10	-3.826	0.000
MTT, s
Before treatment	7.60 ± 1.63	7.80 ± 1.55	-0.622	0.535
After 3 mo of treatment	5.20 ± 0.81	5.83 ± 0.96	-3.511	0.001

Data are presented as mean ± SD. Control group: Treated with transarterial chemoembolization (TACE); Study group: Treated with TACE and radioactive iodine implantation. BF: Blood flow; BV: Blood volume; HAF: Hepatic artery flow; MTT: Mean transit time; PS: Permeability surface.

Table 5 Comparison of survival rates between the two groups

Group	n	1 yr	2 yr	3 yr
Study group	49	46 (93.88)	34 (69.39)	21 (42.86)
Control group	49	44 (89.8)	30 (61.22)	13 (26.53)
χ2 value		0.544	0.721	2.882
P value		0.461	0.396	0.090

Data are presented as n (%). Control group: Treated with transarterial chemoembolization (TACE); Study group: Treated with TACE and radioactive iodine implantation.